What is the rank of RANKL in spondylarthritis?

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 641-644

  Loddenkemper, K ^a   Burmester, G R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DENOSUMAB; DENUSOMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BONE ATROPHY; BONE EROSION; EDITORIAL; ENTHESITIS; HUMAN; JOINT DESTRUCTION; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

EID: 40549145837     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23289     Document Type: Editorial

References (28)

1. 1 Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008 ; 58: 718–29.
2. 2 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 ; 89: 309–19.
3. 3 Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 ; 139: 1329–37.
4. 4 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis‐inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998 ; 95: 3597–602.
5. 5 Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T‐cell growth and dendritic‐cell function. Nature 1997 ; 390: 175–9.
6. 6 Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL‐RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006 ; 12: 17–25.
7. 7 Fata JE, Kong YY, Li J, Sasaki T, Irie‐Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin‐ligand is essential for mammary gland development. Cell 2000 ; 103: 41–50.
8. 8 Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006 ; 107: 289–98.
9. 9 Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, et al. Receptor activator of NF‐κB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006 ; 26: 1002–13.
10. 10 Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005 ; 1: 47–54.
11. 11 Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004 ; 292: 490–5.
12. 12 Boyce BF, Xing L, Chen D. Osteoprotegerin, the bone protector, is a surprising target for β‐catenin signaling. Cell Metab 2005 ; 2: 344–5.
13. 13 Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001 ; 44: 1003–12.
14. 14 Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001 ; 40: 623–30.
15. 15 Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor‐α in bone destruction in rheumatoid arthritis. Bone 2002 ; 30: 340–6.
16. 16 Kubota A, Hasegawa K, Suguro T, Koshihara Y. Tumor necrosis factor‐α promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004 ; 31: 426–35.
17. 17 Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991 ; 34: 1218–27.
18. 18 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31: 315–24.
19. 19 Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF‐κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002 ; 61: 1047–54.
20. 20 Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003 ; 42: 123–34.
21. 21 Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Kohler D, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006 ; 54: 2845–51.
22. 22 Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005 ; 115: 1571–9.
23. 23 Bramlage CP, Haupl T, Kaps C, Ungethum U, Krenn V, Pruss A, et al. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2006 ; 8: R58.
24. 24 Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf‐1 is a master regulator of joint remodeling. Nat Med 2007 ; 13: 156–63.
25. 25 Saidenberg‐Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen‐Solal ME. TNF‐α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen‐induced arthritis. Bone 2004 ; 35: 1200–7.
26. 26 Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 ; 16: 348–60.
27. 27 Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003 ; 97 (3 Suppl): 887–92.
28. 28 Schwarz EM, Ritchlin CT. Clinical development of anti‐RANKL therapy. Arthritis Res Ther 2007 ; 9 Suppl 1: S7.